Under the terms of the agreement, the financial details of which were not disclosed, Bio-Rad will have the right to develop the heparin binding protein marker for use on its proprietary laboratory instruments worldwide.
Under the terms of the agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally. Additional terms of the deal were not disclosed.
With FDA clearance, the test, which had been available outside the US, will now become available in the US.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.